Press Releases

Date	Title and Summary	Additional Formats
Toggle SummarySep112019	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has Read All »	View HTML
Toggle SummarySep122019	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML
Toggle SummarySep182019	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummarySep302019	Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies State-of-the-Art Facility Designed to use Clonal Master iPSC Lines as Renewable Cell Source for Manufacture of Off-the-Shelf Product Pipeline SAN DIEGO , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the Read All »	View HTML
Toggle SummaryOct292019	Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results SAN DIEGO , Oct. 29, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live Read All »	View HTML
Toggle SummaryNov052019	Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress First Patients Treated with FT516, an Off-the-Shelf NK Cell Cancer Immunotherapy for AML and for B-cell Lymphoma in Combination with Rituximab Received FDA Clearance of IND Application for FT596, an Off-the-Shelf, Multi-Antigen Targeted CAR NK Cell Product Candidate Opened State-of-the-art cGMP Read All »	View HTML
Toggle SummaryNov062019	Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting FT596 Selected by ASH for Feature at “CAR-T and Beyond” P ress Conference on December 7 Two Oral and Four Poster Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation Company to Host Investor Event at ASH on December 6 SAN DIEGO , Nov. Read All »	View HTML
Toggle SummaryNov142019	Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference SAN DIEGO , Nov. 14, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Scott Wolchko , President and Chief Executive Read All »	View HTML
Toggle SummaryNov272019	Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference SAN DIEGO , Nov. 27, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that Dan Shoemaker , Ph.D., Chief Scientific Officer, Read All »	View HTML
Toggle SummaryDec072019	Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle No Dose-limiting Toxicities or FT500-related SAEs Reported in First 12 Patients Treated with FT500 for Advanced Solid Tumors Favorable Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.